Mirikizumab linked to clinical remission in pediatric UC
NASHVILLE, Tenn. — Among children with ulcerative colitis, mirikizumab achieved clinical and endoscopic remission rates exceeding those of historical adult outcomes with placebo at week 12, according to data presented. Researchers also reported associations between mirikizumab (Omvoh, Eli Lilly & Co.) and clinical, sym
